GCM
VERV

Ghisallo Capital Management’s Verve Therapeutics VERV Stock Holding History

Ghisallo Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$705K – 526
2021
Q3 		$705K Buy
15,000
+5,000
+50% +$294K 0.03% 391
2021
Q2 		$603K Buy
+10,000
New +$415K 0.02% 374

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ghisallo Capital Management's VERV Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Verve Therapeutics (VERV) in Q4 2021, closing a stake of 15,000 shares — an estimated $705K sold.

Ghisallo Capital Management first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $705K in Q3 2021. 96 funds tracked by Wall St. Rank hold VERV as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Verve Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Verve Therapeutics shares in Q4 2021, an estimated $705K.
  • Ghisallo Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Verve Therapeutics position peaked at $705K in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.